Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy
- Conditions
- Interventions
- First Posted Date
- 2014-04-24
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 40
- Registration Number
- NCT02121847
A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Participants With Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 284
- Registration Number
- NCT02121262
- Locations
- 🇨🇳
Wenzhou Ophthalmic Centre, Wenzhou, Zhejiang, China
🇵🇭Peregrine Eye and Laser Institute, Makati City, Metro Manila, Philippines
🇨🇳Beijing Hospital, Beijing, Beijing, China
A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye
- Conditions
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 80
- Registration Number
- NCT02117687
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
- Conditions
- Interventions
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Allergan
- Target Recruit Count
- 258
- Registration Number
- NCT02116361
- Locations
- 🇺🇸
Schuster Medical Research Institute, Sherman Oaks, California, United States
🇺🇸InSite Clinical Research, DeSoto, Texas, United States
🇺🇸Zain Research LLC, Richland, Washington, United States
Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
- Conditions
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 100
- Registration Number
- NCT02097719
OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)
- Conditions
- Interventions
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- Allergan
- Target Recruit Count
- 56
- Registration Number
- NCT02097121
- Locations
- 🇫🇷
Duplicate_CHU Bordeaux-Hopital Pellegrin /ID# 237392, Bordeaux, France
🇩🇪Evangelisches Krankenhaus Bielefeld /ID# 235234, Bielefeld, Germany
🇨🇦Alberta Children's Hospital /ID# 237510, Calgary, Alberta, Canada
A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea
- First Posted Date
- 2014-03-24
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 440
- Registration Number
- NCT02095158
A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Allergan
- Target Recruit Count
- 310
- Registration Number
- NCT02087085
- Locations
- 🇺🇸
Northern California Retina Vitreous Associates, Mountain View, California, United States
🇺🇸Retinal Consultants of Arizona, Ltd., Retinal Research Institute, Phoenix, Arizona, United States
🇺🇸Raj K. Maturi, MD, Indianapolis, Indiana, United States
AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis
- First Posted Date
- 2014-03-10
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 140
- Registration Number
- NCT02082262
Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Allergan
- Target Recruit Count
- 55
- Registration Number
- NCT02072928
- Locations
- 🇧🇪
CHU de Liège, Esneux, Belgium
🇧🇪UZA, Edegem, Belgium
🇧🇪Maria Ziekenhuis Noord-Limburg, Overpelt, Belgium